Dacarbazine

Generic Name
Dacarbazine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H10N6O
CAS Number
4342-03-4
Unique Ingredient Identifier
7GR28W0FJI
Background

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions
Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Phase 3
Terminated
Conditions
Metastatic Melanoma
Interventions
Drug: Dacarbazine
Drug: Masitinib
First Posted Date
2011-01-21
Last Posted Date
2020-11-05
Lead Sponsor
AB Science
Target Recruit Count
134
Registration Number
NCT01280565
Locations
🇺🇸

Blumenthal Cancer Centre, Charlotte, North Carolina, United States

🇫🇷

Centre Hospitalier LE MANS, Le Mans, France

🇨🇿

University Hospital Hradec Králové, Hradec Králové, Czechia

and more 6 locations

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

First Posted Date
2010-12-01
Last Posted Date
2015-08-13
Lead Sponsor
Fondazione Michelangelo
Target Recruit Count
331
Registration Number
NCT01251107
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Phase 2
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Bevacizumab
Drug: Dacarbazine
First Posted Date
2010-07-16
Last Posted Date
2017-04-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT01164007
Locations
🇮🇹

Istituto Europeo Di Oncologia, Milano, Lombardia, Italy

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
Drug: rIL-21
Drug: Dacarbazine
First Posted Date
2010-06-29
Last Posted Date
2023-08-22
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
64
Registration Number
NCT01152788
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 16 locations

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

First Posted Date
2010-06-14
Last Posted Date
2017-07-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT01143402
Locations
🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Mount Sinai Medical Center, Miami Beach, Florida, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 30 locations

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1
Completed
Conditions
Stage IV Melanoma
Interventions
Drug: Lenvatinib
Drug: Dacarbazine
First Posted Date
2010-05-31
Last Posted Date
2016-10-10
Lead Sponsor
Eisai Inc.
Target Recruit Count
97
Registration Number
NCT01133977

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

First Posted Date
2010-05-28
Last Posted Date
2021-06-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
164
Registration Number
NCT01132807
Locations
🇺🇸

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States

🇺🇸

UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 92 locations

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

First Posted Date
2010-04-09
Last Posted Date
2019-02-26
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
38
Registration Number
NCT01100528
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

First Posted Date
2010-02-02
Last Posted Date
2014-12-18
Lead Sponsor
Seagen Inc.
Target Recruit Count
51
Registration Number
NCT01060904
Locations
🇺🇸

MD Anderson Cancer Center / University of Texas, Houston, Texas, United States

🇺🇸

UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

First Posted Date
2010-01-26
Last Posted Date
2018-03-22
Lead Sponsor
University of Cologne
Target Recruit Count
30
Registration Number
NCT01056679
Locations
🇩🇪

1st Dept. of Medicine, Cologne University Hospital, Cologne, NRW, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy